Galapagos (GLPG) has released an update.
Galapagos NV has released promising new data for its CD19 CAR-T candidate, GLPG5101, showing high complete response rates and a favorable safety profile in a Phase 1/2 study for non-Hodgkin lymphoma. The results, to be presented at the EHA 2024 Congress, also highlight the success of the company’s decentralized T-cell manufacturing platform, which has enabled a rapid median vein-to-vein time of just seven days. This breakthrough has the potential to significantly improve treatment options for patients with rapidly progressing cancers.
For further insights into GLPG stock, check out TipRanks’ Stock Analysis page.
